AKT1 and melanoma: Patients with refractory melanoma brain metastasis may still stand to benefit from this combination approach given that brain metastases have increased expression of PI3K/AKT pathway genes relative to extracranial metastases (Chen et al., 2014; Fischer et al., 2019) and show high sensitivity to PI3K/AKT inhibition in vivo (Aasen et al., 2019; Amaral et al., 2020; Brastianos et al., 2015).